News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Preclinical Research with Proteonomix, Inc. (PROT)’s UMK-121 Featured in Oral Presentation at the International Society for Cellular Therapy 18th Annual Meeting


6/7/2012 10:12:23 AM

HAWTHORNE, N.J.--(BUSINESS WIRE)--Proteonomix, Inc. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announces the oral presentation by Chief Scientific Officer Ian McNiece, Ph.D., of research related to the Company’s UMK-121 technology today at the International Society for Cellular Therapy (ISCT) 18th Annual Meeting underway in Seattle.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES